Gilead's breast cancer drug fails to meet main goal of late-stage study

Reuters
Nov 07
<a href="https://laohu8.com/S/GILD">Gilead</a>'s breast cancer drug fails to meet main goal of late-stage study

Nov 7 (Reuters) - Gilead Sciences GILD.O said on Friday its breast cancer drug Trodelvy failed to meet the main goal of a late-stage study.

(Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10